In the US and UK, guidelines recommend that SLS-CRC individuals undergo tumor genomic sequencing to re-classify the 50–75% of cases with sporadic cancers resulting from biallelic somatic mutations in an MMR gene [17, 43–46]. Here, MRC1 is linked to neoplasm.